helicobacter%20pylori%20infection
HELICOBACTER PYLORI INFECTION
Helicobacter pylori is a spiral-shaped gram-negative bacterium involved in the development of gastritis, duodenal and gastric ulcers, and gastric cancer.
Infection is strongly associated with the development of gastric epithelial and lymphoid malignancies.
Acute infection is mostly asymptomatic and is acquired through human-to-human contact via gastro-oral and fecal-oral routes.
Adaptability in gastric conditions and production of urease allow it to colonize the stomach.

Helicobacter pylori Infection Drug Information

Drug Information

Indication: Short-term treatment of upper & lower resp tract, skin & soft tissue, GUT infections. Tab & inj Sh...

Indication: Acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired & nosoco...

Indication: Peptic ulcer disease associated w/ H pylori.

Indication: Infections of nose-pharynx tract (tonsillitis, pharyngitis) & of paranasal sinuses; lower resp tract: bron...

Indication: Healing of gastric ulcers associated w/ NSAID therapy. Prevention of gastric & duodenal ulcers associated ...

Indication: Gastric & duodenal ulcer; reflux esophagitis (erosive esophagitis). Maintenance treatment of reflux esopha...

Indication: Healing & maintenance of erosive or ulcerative GERD. Healing of duodenal ulcers. Pathological hypersecreto...

Indication: Infections due to gm -ve & +ve organisms & non-penicillinase-producing staph.

Indication: Skin & skin structure, acute & chronic resp, complicated & uncomplicated, acute & chronic GUT ...

1  /  11
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 25 Nov 2020
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.